Radiotherapy
Expressions of PBK and MMP-9 and their effect on concurrent chemoradiotherapy in cervical cancer
Sun Xiaoge, Bao Yingna, Qiu Hui, Shi Jing, Zhang Wei, Yu Zhilong, Xie Conghua
Published 2018-07-25
Cite as Chin J Radiol Med Prot, 2018,38(7): 529-534. DOI: 10.3760/cma.j.issn.0254-5098.2018.07.009
Abstract
ObjectiveTo investigate the expression of DNA damage repair factor PDZ binding kinase (PBK) and matrix metalloproteinase 9 (MMP-9) in cervical cancer and the effect on clinical outcomes of concurrent chemoradiotherapy.
MethodsA total of 65 cervical cancer pathological specimens were collected from January 2014 to July 2016. Immunohistochemistry was used to detect PBK and MMP-9 expression in the specimens.External irrsdeation was treated with intensity-modulated radiation therapy at a dose of 50 Gy/25 F. After 18 times of external irradiation, high-dose rate postoperative treatment was giver at a dose of 30-36 Gy/5-6 F which lasts 3-4 weeks. Weekly chemotherapy with Cisplatin(DDP) begins simultaneously at the beginning of external irradiation. DDP was administered intravenously at a dosage of 40 mg/m2 for 2 to 6 week. All patients were followed-up as routine. The relationship between clinical characteristics and prognosis of patients and the expression of PBK and MMP-9 were analyzed.
ResultsPBK was expressed in 92.3% of tissues and MMP-9 was expressed in 69.2% of tissues. The expression of PBK was positively associated with overall survival (OS) and disease progression-free survival (PFS) of cervical cancer patients (χ2=4.324, 8.068, P<0.05). The expression of MMP-9 was related with PFS (χ2=5.134, P<0.05). Patients with PBK and MMP-9 expression suffered poor OS and PFS (χ2=5.382, 9.364, P<0.05).
ConclusionsPBK and MMP-9 could be a biomarker to predict the prognosis of cervical cancer.
Key words:
PBK(PDZ binding kinase); Matrix metalloproteinase 9(MMP-9); Concurrent chemoradiotherapy; Cervical cancer
Contributor Information
Sun Xiaoge
Department of Radiotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
Bao Yingna
Department of Radiotherapy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
Qiu Hui
Department of Radiotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
Shi Jing
Department of Radiotherapy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
Zhang Wei
Department of Radiotherapy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
Yu Zhilong
Department of Radiotherapy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
Xie Conghua
Department of Radiotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
